Partnering Purpose: BI Gives Back | Boehringer Ingelheim US
Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.
Search
Employees join #stayhomeandfoster movement
Employees join #stayhomeandfoster movement
A legacy in the making: Working together to spark meaningful change
Discover Jim’s passion for being an advocate for meaningful causes.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic
Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
US Privacy Statement
US Privacy Statement
Help in all situations in life
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US
Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
Cookie Statement
Cookie Statement
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
She finds purpose in the saddle and pursues a passion for horses – at home and work
She finds purpose in the saddle and pursues a passion for horses – at home and work
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US
Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis